Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06FGJ
|
||||
| Former ID |
DIB000195
|
||||
| Drug Name |
Protexia
|
||||
| Synonyms |
RBChE; PEG-rBChE; PEGylated butyrylcholinesterase (recombinant human, nerve agent exposure), PharmAthene
|
||||
| Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Phase 1 | [1] | ||
| Company |
Nexia Biotechnologies Inc
|
||||
| Target and Pathway | |||||
| Target(s) | Cholinesterase | Target Info | Modulator | [2] | |
| PANTHER Pathway | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | ||||
| Muscarinic acetylcholine receptor 2 and 4 signaling pathway | |||||
| Nicotinic acetylcholine receptor signaling pathway | |||||
| WikiPathways | Irinotecan Pathway | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00744146) First Time in Human Study of Protexia. U.S. National Institutes of Health. | ||||
| REF 2 | In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.